Cargando…

The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients

After five years of endocrine therapy, patients with ER+ (estrogen receptor positive) breast cancer face the question of the benefit of further treatment. Ten years of endocrine therapy has been demonstrated to improve survival compared to five years. However, the individual benefit of continuation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pachmann, Katharina, Schuster, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266844/ https://www.ncbi.nlm.nih.gov/pubmed/30380648 http://dx.doi.org/10.3390/cancers10110407

Ejemplares similares

Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer
por: Pizon, Monika, et al.
Publicado: (2018)

Influence of adjuvant radiotherapy on circulating epithelial tumor cells and circulating cancer stem cells in primary non-metastatic breast cancer
por: Schott, Dorothea Sonja, et al.
Publicado: (2021)

Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring
por: Pachmann, Katharina, et al.
Publicado: (2005)

Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients
por: Mäurer, Matthias, et al.
Publicado: (2021)

Monitoring of circulating epithelial tumor cells using the Maintrac(®) method and its potential benefit for the treatment of patients with colorectal cancer
por: Gold, Madeleine, et al.
Publicado: (2021)

Insulin-Like Growth Factor Receptor I (IGF-IR) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Are Expressed on the Circulating Epithelial Tumor Cells of Breast Cancer Patients
por: Pizon, Monika, et al.
Publicado: (2013)

Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy
por: Pachmann, Katharina, et al.
Publicado: (2010)

Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(® )is a predictor for relapse: A preliminary report
por: Rolle, Axel, et al.
Publicado: (2005)

Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
por: Schott, Dorothea Sonja, et al.
Publicado: (2017)

Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma
por: Pachmann, Katharina, et al.
Publicado: (2011)

Chick Chorioallantoic Membrane (CAM) Assays as a Model of Patient-Derived Xenografts from Circulating Cancer Stem Cells (cCSCs) in Breast Cancer Patients
por: Pizon, Monika, et al.
Publicado: (2022)

Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging
por: Willecke-Hochmuth, Regina, et al.
Publicado: (2016)

Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells
por: Camara, Oumar, et al.
Publicado: (2006)

Heterogeneity of circulating epithelial tumour cells from individual patients with respect to expression profiles and clonal growth (sphere formation) in breast cancer
por: Pizon, M, et al.
Publicado: (2013)

The number of tumorspheres cultured from peripheral blood is a predictor for presence of metastasis in patients with breast cancer
por: Pizon, Monika, et al.
Publicado: (2016)

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
por: Paoletti, Costanza, et al.
Publicado: (2021)

Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer
por: Mäurer, Matthias, et al.
Publicado: (2022)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
por: Martínez-Sáez, Olga, et al.
Publicado: (2021)

Prognostic Relevance of Estrogen Receptor Status in Circulating Tumor Cells in Breast Cancer Patients Treated With Endocrine Therapy
por: Zhou, Ying, et al.
Publicado: (2022)

Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring
por: ALEMZADEH, EFFAT, et al.
Publicado: (2023)

Tumor Cell Seeding During Surgery—Possible Contribution to Metastasis Formations
por: Katharina, Pachmann
Publicado: (2011)

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
por: Shao, Bin, et al.
Publicado: (2022)

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
por: Lupini, Laura, et al.
Publicado: (2018)

Pharmacogenomics of endocrine therapy in breast cancer
por: Ingle, James N
Publicado: (2013)

Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2021)

High depletion of breast cancer cells from the peripheral blood with the method of non-specific separation
por: Payer, Petra, et al.
Publicado: (2020)

Circulating tumor cells in breast cancer
por: Pukazhendhi, Geetha, et al.
Publicado: (2014)

Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics
por: Chandler, Young, et al.
Publicado: (2021)

Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients
por: Sajdik, Constantin, et al.
Publicado: (2022)

Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies
por: Shawky, Michael S., et al.
Publicado: (2016)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Pathways to Endocrine Therapy Resistance in Breast Cancer
por: Haque, Md. Moquitul, et al.
Publicado: (2019)

The immunomodulatory effects of endocrine therapy in breast cancer
por: Huang, Huanhuan, et al.
Publicado: (2021)

Updates in endocrine therapy for metastatic breast cancer
por: Manohar, Poorni M., et al.
Publicado: (2022)

Epithelial Cell Dissemination and Readhesion: Analysis of Factors Contributing to Metastasis Formation in Breast Cancer
por: Hekimian, Katya, et al.
Publicado: (2012)

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells
por: Castellaro, Andrés M., et al.
Publicado: (2019)

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer
por: Yuan, Jie, et al.
Publicado: (2023)

Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value
por: Fabisiewicz, Anna, et al.
Publicado: (2020)

Elastosis and response to endocrine therapy in human breast cancer.
por: Masters, J. R., et al.
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_d01fg4lfq9f8d1eq1va867kmva